Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment

Autor: Janaka Karalliedde, Peter A. Senior, Anna M. G. Cali, Robert A. Ritzel, Serge Halimi, F. Javier Escalada, Mireille Bonnemaire, Lydie Melas-Melt
Rok vydání: 2018
Předmět:
Male
medicine.medical_specialty
Evening
insulin analogues
Endocrinology
Diabetes and Metabolism

Insulin Glargine
Renal function
030209 endocrinology & metabolism
Type 2 diabetes
030204 cardiovascular system & hematology
Kidney
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Endocrinology
Internal medicine
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Diabetic Nephropathies
basal insulin
Aged
Randomized Controlled Trials as Topic
Insulin glargine
business.industry
Significant difference
nutritional and metabolic diseases
Original Articles
Middle Aged
medicine.disease
Hypoglycemia
Confidence interval
glycaemic control
Treatment Outcome
Clinical Trials
Phase III as Topic

Diabetes Mellitus
Type 2

meta‐analysis
Meta-analysis
Relative risk
Original Article
Female
type 2 diabetes
business
hormones
hormone substitutes
and hormone antagonists

hypoglycaemia
Glomerular Filtration Rate
medicine.drug
Zdroj: Diabetes, Obesity & Metabolism
ISSN: 1462-8902
Popis: AIM To investigate the impact of renal function on the safety and efficacy of insulin glargine 300 U/mL (Gla-300) and insulin glargine 100 U/mL (Gla-100). MATERIALS AND METHODS A meta-analysis was performed using pooled 6-month data from the EDITION 1, 2 and 3 trials (N = 2496). Eligible participants, aged ≥18 years with a diagnosis of type 2 diabetes (T2DM), were randomized to receive once-daily evening injections of Gla-300 or Gla-100. Pooled results were assessed by two renal function subgroups: estimated glomerular filtration rate (eGFR)
Databáze: OpenAIRE